Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses-MedSci.cn

Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses

Olszewski, A; Avigdor, A; Babu, S; Levi, I; Eradat, H; Abadi, U; Holmes, H; McKinney, M; Woszczyk, D; Giannopoulos, K; Jurczak, W; McCord, R; Xie, YY; Zhou, MZ; Qayum, N; O'Hear, C; Sellam, G; Horowitz, N

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021; 21 (): S395

科室
- - 订阅+
  - 更多科室
工具
服务